Diagnostics and treatment of polymyalgia rheumatica

被引:7
作者
Dejaco, C. [1 ]
Matteson, E. L. [2 ,3 ,4 ,5 ]
Buttgereit, F. [6 ]
机构
[1] Med Univ Graz, Klin Abt Rheumatol, Graz, Austria
[2] Mayo Clin, Div Rheumatol, Dept Internal Med, Coll Med, Rochester, MN USA
[3] Mayo Clin, Div Epidemiol, Dept Internal Med, Coll Med, Rochester, MN USA
[4] Mayo Clin, Div Rheumatol, Dept Hlth Sci Res, Coll Med, Rochester, MN USA
[5] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Coll Med, Rochester, MN USA
[6] Charite, Med Klin Schwerpunkt Rheumatol & Klin Immunol, Charitepl 1, D-10117 Berlin, Germany
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2016年 / 75卷 / 07期
关键词
Epidemiology; Treatment; Monitoring; Arthritis; Autoimmune diseases; GIANT-CELL ARTERITIS; PROVISIONAL CLASSIFICATION CRITERIA; TERM-FOLLOW-UP; RHEUMATISM/AMERICAN COLLEGE; EUROPEAN LEAGUE; DOUBLE-BLIND; GLUCOCORTICOID THERAPY; 2015; RECOMMENDATIONS; ONSET; METHOTREXATE;
D O I
10.1007/s00393-016-0105-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymyalgia rheumatica (PMR) is the most common autoimmune inflammatory disease in older persons with an average age of onset of 73 years. Typical symptoms include acute or subacute bilateral shoulder pain with severe stiffness and often neck and bilateral hip pain. Giant cell arteritis (GCA) occurs in approximately 20 % of cases and up to two thirds of patients with GCA have symptoms of PMR. There are many disease which mimic PMR, elderly onset rheumatoid arthritis is frequently misdiagnosed as PMR. Although there are no specific laboratory tests, CaEuroreactive protein and erythrocyte sedimentation rates are elevated in over 90 % of patients. The diagnosis may be aided by imaging, especially ultrasonography and magnetic resonance imaging (MRI). Treatment currently consists of glucocorticoids at an initial dose of 12.5-25 mg prednisone equivalent daily. Treatment duration is typically 2aEuro3 years but may be longer. Under certain conditions low-dose methotrexate can be used as adjuvant therapy.
引用
收藏
页码:687 / 700
页数:14
相关论文
共 64 条
[41]  
Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
[42]   Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR) [J].
Lee, Jung Hwa ;
Choi, Sang Tae ;
Kim, Jin Su ;
Yoon, Bo Young ;
Kwok, Seung-Ki ;
Kim, Hyun-Sook ;
Kim, Yun Sung ;
Song, Jung-Soo ;
Lee, Sang-Heon ;
Kim, Hae-Rim .
RHEUMATOLOGY INTERNATIONAL, 2013, 33 (06) :1475-1480
[43]   A disease activity score for polymyalgia rheumatica [J].
Leeb, BF ;
Bird, HA .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) :1279-1283
[44]   EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT) [J].
Leeb, BF ;
Bird, HA ;
Nesher, G ;
Andel, I ;
Hueber, W ;
Logar, D ;
Montecucco, CM ;
Rovensky, J ;
Sautner, J ;
Sonnenblick, M .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (12) :1189-1194
[45]   Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica [J].
Lopez-Hoyos, M ;
de Alegria, CR ;
Blanco, R ;
Crespo, J ;
Peña, M ;
Rodriguez-Valverde, V ;
Martinez-Taboada, VM .
RHEUMATOLOGY, 2004, 43 (05) :655-657
[46]   Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature [J].
Macchioni, Pierluigi ;
Boiardi, Luigi ;
Catanoso, Mariagrazia ;
Pulsatelli, Lia ;
Pipitone, Nicolo ;
Meliconi, Riccardo ;
Salvarani, Carlo .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2013, 43 (01) :113-118
[47]  
Martínez-Taboada VM, 2000, CLIN EXP RHEUMATOL, V18, pS34
[48]  
Nazarinia AM., 2012, KOOMESH, V14, P265
[49]   Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases [J].
Olivieri, Ignazio ;
Garcia-Porrua, Carlos ;
Padula, Angela ;
Cantini, Fabrizio ;
Salvarani, Carlo ;
Gonzalez-Gay, Miguel A. .
RHEUMATOLOGY INTERNATIONAL, 2007, 27 (10) :927-933
[50]  
Pfeifer EC, 2015, RHEUMATOLOGY S, VS6, DOI [10.4172/2161-1149.S6-003, DOI 10.4172/2161-1149.S6-003]